

# Age-related difference in susceptibility of $Apc^{Min/+}$ mice towards the chemopreventive efficacy of dietary aspirin and curcumin

S Perkins<sup>1</sup>, AR Clarke<sup>2</sup>, W Steward<sup>1</sup> and A Gescher<sup>\*1</sup>

<sup>1</sup>Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK;

<sup>2</sup>Cardiff School of Biosciences, University of Cardiff, UK

The nonsteroidal anti-inflammatory drug aspirin and the spice curcumin retard adenoma formation when administered long-term to  $Apc^{Min/+}$  mice, a model of human familial adenomatous polyposis coli. Both agents interfere with cyclooxygenase activity. When aspirin is administered to  $Apc^{Min/+}$  mice only postweaning, but not before, it is inefficacious, while curcumin given postweaning is active. Here the hypothesis was tested that dietary aspirin (0.05%) or curcumin (0.2%) prevent or delay adenoma formation in offsprings when administered to  $Apc^{Min/+}$  mothers and up to the end of weaning, but not afterwards. Whereas curcumin was without effect when administered in this way, aspirin reduced numbers of intestinal adenomas by 21%. When aspirin given up to the end of weaning was combined with curcumin administered from the end of weaning for the rest of the animals' lifetime, intestinal adenoma numbers were reduced by 38%. The combination was not superior to intervention postweaning with curcumin alone. These results show that aspirin exerts chemopreventive activity in the  $Apc^{Min/+}$  mouse during tumour initiation/early promotion, while curcumin is efficacious when given at a later stage of carcinogenic progression. Thus, the results suggest that in this mouse model aspirin and curcumin act during different 'windows' of neoplastic development.

British Journal of Cancer (2003) 88, 1480–1483. doi:10.1038/sj.bjc.6600900 www.bjcancer.com

© 2003 Cancer Research UK

**Keywords:**  $Apc^{Min/+}$  mice; aspirin; curcumin; chemoprevention

It has been estimated that over half of the Western population develops benign adenomatous polyps during its lifetime, and that 10% of these tumours proceed to malignant colorectal carcinoma (Kinzler and Vogelstein, 1996). This realisation has engendered an intense search for efficacious chemopreventive intervention strategies using animal models of premalignant and malignant colorectal cancer. The 'multiple intestinal neoplasia' ( $Apc^{Min/+}$ ) mouse model of human familial adenomatous polyposis (Moser *et al*, 1990) has been instrumental in the identification of several potential chemopreventive drug candidates, among them nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified by sulindac (Boolbol *et al*, 1996) and aspirin (Mahmoud *et al*, 1998), and the spice curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (Mahmoud *et al*, 2000; Perkins *et al*, 2002). Curcumin is the major yellow pigment extracted from turmeric, the powdered rhizome of the herb *Curcuma longa*. Interestingly, the evidence for the chemopreventive efficacy of aspirin in  $Apc^{Min/+}$  mice, and similar models involving mutant *Apc* is ambiguous. In two studies in  $Apc^{Min/+}$  mice, aspirin suppressed malignancy (Barnes and Lee, 1998; Mahmoud *et al*, 1998), while in two others in  $Apc^{Min/+}$  and  $Apc^{1638N/+}$  mice it failed to show efficacy (Williamson *et al*, 1999; Chiu *et al*, 2000). This discrepancy is probably related to differences in the aspirin regimen used in these studies, a notion borne out by the recent finding that continual exposure of  $Apc^{Min/+}$  mice to aspirin from the point of conception onwards suppressed tumorigenesis, while exposure

during adulthood only did not (Sansom *et al*, 2001). It is not known whether aspirin retains its efficacy in this model when given only during embryogenesis and weaning, without being present in the diet thereafter. Mechanistically curcumin shares with aspirin the ability to interfere with levels of functional cyclooxygenase (COX) enzymes. While aspirin inhibits COX enzyme activity (Vane, 1971), curcumin interferes with the NF $\kappa$ B-mediated activation of COX-2 transcription (Plummer *et al*, 1999). An attractive feature of curcumin is the fact that it fails to elicit detrimental gastrointestinal side effects associated with traditional NSAIDs, such as aspirin. In the study described here, we wished to explore whether dietary aspirin and/or curcumin retard neoplastic development in the  $Apc^{Min/+}$  mouse when administered *in utero* and during weaning, without being present in the diet thereafter. Aspirin was found to be efficacious when administered in this way, but curcumin was inactive. Therefore, the hypothesis was tested that a combination of aspirin *in utero* and during weaning followed by curcumin postweaning results in additive or synergistic adenoma-suppressing activity, as this regimen might exploit age-related differences in susceptibility of  $Apc^{Min/+}$  mice to the cancer-delaying effects of these agents.


## MATERIALS AND METHODS

Experiments in mice were conducted as stipulated by the Animals (Scientific Procedures) Act 1986 Project Licence 80/1250 granted to Leicester University by the UK Home Office, and the experimental design was vetted and approved by the Leicester University Ethical Committee for Animal Experimentation. C57BL/6J male  $Apc^{Min/+}$  mice and C57BL/6J female wild-type mice were mated to maintain

\*Correspondence: Dr A Gescher; E-mail: ag15@le.ac.uk

Received 18 November 2002; revised 29 January 2003; accepted 18 February 2003


the *Apc<sup>Min/+</sup>* breeding colony. Tissue samples were obtained by ear punch and genotyped for *Min/+* status by PCR and *HindIII* digest of the product as described previously (Luongo *et al*, 1994). Curcumin and aspirin were purchased from Apin Chemicals (Abingdon, UK) and Sigma (Poole, UK), respectively. The purity of curcumin was verified by HPLC analysis; this material contained 3% desmethoxycurcumin. Aspirin or curcumin was blended into RM3 high protein breeders diet (SDS, Witham, UK), using a mechanical mixer to ensure uniform distribution, which was confirmed by HPLC analysis. Breeding pairs were established and fed RM3 maintenance diet or RM3 containing either 0.05% aspirin, which translates into 75 mg kg<sup>-1</sup> pd, or 0.2% curcumin, which translates into 300 mg kg<sup>-1</sup> pd. After 2 weeks, the females were removed and maintained on their respective diets, until the offspring were removed and genotyped at 3 weeks of age. At 30 days, the offspring with the *Min/+* phenotype were divided into three intervention groups of eight to 10 animals (Figure 1): (i) mice that received RM3 control diet, (ii) mice that received either aspirin or curcumin in RM3 diet perinatally and during days 1–30, followed by RM3 diet omitting aspirin/curcumin to the end of the experiment; (iii) mice that received aspirin perinatally and during days 1–30, followed by curcumin in RM3 diet from weaning to the end of the experiment. The early administration regimen will be referred to in the following as ‘*in utero* and during weaning’, the late regime as ‘postweaning’. An experiment, in which mice received curcumin postweaning to the end of the experiment, has been performed previously in this laboratory (Perkins *et al*, 2002) and was not repeated here to reduce animal usage. At 120 days, mice were killed by cardiac exsanguination under terminal halothane anaesthesia. The gastrointestinal tract was removed, and multiplicity, location and size of adenomas were recorded as described previously (Perkins *et al*, 2002). Adenoma numbers values were subjected to statistical evaluation by ANOVA using Excel and Minitab software packages (Microsoft Windows, 1997). Statistical significance ( $P < 0.05$ ) was established by *post hoc* Tukey’s pairwise comparison. The haematocrit, the percentage of blood volume occupied by packed erythrocytes, was determined as described previously (Strumia *et al*, 1954) using blood samples collected and drawn by capillary force into heparinised microhaematocrit tubes (75 mm, Richardson’s, Leicester, UK).



**Figure 1** Experimental design for the evaluation of the chemopreventive efficacy of aspirin (0.05%) or curcumin (0.2%) administered in the diet *in utero* and during weaning, or of curcumin from termination of weaning to the end of the experiment, or of the combination of aspirin *in utero* and during weaning followed by curcumin postweaning. RM3 was the control diet. The study was terminated after 120 days. For details of animals and treatments see Materials and Methods.

## RESULTS AND DISCUSSION

Administration of aspirin (0.05%) *in utero* and during weaning in *Apc<sup>Min/+</sup>* mice and maintaining mice on aspirin-free diet thereafter, reduced tumour burden in the small intestine by 21% (Figure 2). This result is consistent with the notion that the majority of adenomas in *Apc<sup>Min/+</sup>* mice are fixed already either *in utero* or perinatally just after birth (Shoemaker *et al*, 1995; Ritland and Gendler, 1999). It suggests, for the first time, that interference with tumour initiation and/or early promotion in *Apc<sup>Min/+</sup>* mice can have a long-term beneficial consequence, even if the chemopreventive stimulus is discontinued postweaning. A similar reduction was observed in the colon, however overall colonic adenoma burden was so low that the difference between exposed and unexposed mice was not significant (result not shown). The modest but significant reduction of intestinal adenoma burden by aspirin is consistent with previous work according to which long-term dietary administration of aspirin from conception onwards increased the survival of *Apc<sup>Min/+</sup>* mice, while exposure during adulthood only did not (Sansom *et al*, 2001). The failure of aspirin to attenuate neoplastic development in *Apc<sup>Min/+</sup>* mice, when administered postweaning only, has been demonstrated in at least three other studies (Williamson *et al*, 1999; Chiu *et al*, 2000; Reuter



**Figure 2** Effect on adenoma burden in the small intestine of *Apc<sup>Min/+</sup>* mice of aspirin ('asp', 0.05% in the diet, open bar) or curcumin ('curc', 0.2% in the diet) administered *in utero* and during weaning ('preweaning', bar striped diagonally bottom left to top right), or of curcumin administered postweaning to the end of the lifetime ('postweaning', bar striped diagonally top left to bottom right), or of the combination of aspirin *in utero* and during weaning followed by curcumin postweaning (black bar). Adenoma burden is expressed as percentage of number of adenomas in untreated mice, the number of mice used per group was eight to 10. The value for the effect of curcumin postweaning (bar striped diagonally top left to bottom right) was obtained previously (Perkins *et al*, 2002) and has been included for comparison; this experiment was not repeated here to minimise animal usage. The results originate from three separate experiments, and number of intestinal adenomas in the control (untreated) groups were as follows: experiment described by open and black bars:  $132 \pm 12$ , experiment described by bar diagonally striped bottom left to top right:  $117 \pm 13$ , experiment described by bar striped diagonally top left to bottom right:  $115 \pm 12$ . The s.d.s of adenoma number values for the different interventions are 12% of the mean, or smaller. Asterisk indicates that the number of adenomas is significantly different from that in control (untreated) animals ( $P < 0.05$ ). For details of animals and treatments and statistical evaluation, see Materials and Methods.

*et al*, 2002). In contrast, there are reports that document convincingly the ability of two NSAIDs other than aspirin, piroxicam (Ritland and Gendler, 1999) and celecoxib (Jacoby *et al*, 2000b), to decrease the number of established polyps and to prevent the development of nascent ones, when they are administered at a late stage during the lifetime of  $Apc^{Min/+}$  mice.


Detailed analysis of the results obtained for aspirin reveals that administration *in utero* and during weaning reduced the number of middle-sized adenomas, those of 1–3 mm diameter, in both the middle and distal regions of the small intestine (Figure 3). The decrease in tumour size intimates that aspirin delays adenoma development, rather than totally suppressing the emergence of a subset of adenomas. The efficacy of aspirin when it is administered *in utero* and during weaning only suggests that in the  $Apc^{Min/+}$  mouse there is a 'window of opportunity' for preventive intervention using aspirin, and this window occurs in very young mice. A similar window of susceptibility allowing regulation of tumour development in  $Apc^{Min/+}$  mice has been suggested by results of experiments in which the effect of the carcinogen *N*-ethyl-*N*-nitrosourea on the formation of crypts and adenomas was studied (Shoemaker *et al*, 1995).

In contrast to aspirin, dietary curcumin (0.2%) administered *in utero* and during weaning only, failed to affect adenoma number (Figure 2). This finding suggests that high preventive efficacy at the stage of tumour initiation/early promotion is not a generic feature of all agents that target COX enzymes. In contrast, curcumin administered later, that is, from the end of weaning for the lifetime, reduced intestinal adenoma burden in  $Apc^{Min/+}$  mice by 39%, compared to untreated mice (Figure 2, reference Perkins *et al*, 2002).

These results warrant interpretation in terms of our knowledge of the pharmacokinetics of aspirin and curcumin. Aspirin is efficiently absorbed, rapidly distributed and swiftly hydrolysed in the biophase to salicylate, which in turn is eliminated via the

kidneys and/or undergoes phase II drug metabolism (Needs and Brooks, 1985). Furthermore, salicylate generated by hydrolysis of aspirin reaches breast milk readily (Findlay *et al*, 1981). When administered to the mother, salicylates are rapidly transferred to the fetus (Schoenfeld *et al*, 1992). As aspirin has a short half-life, only a small amount of unmetabolised drug reaches the fetus, which is therefore exposed mainly to its metabolite salicylate. Compared to the adult organism, the fetus has reduced abilities of salicylate plasma protein binding, biotransformation and drug elimination. Therefore, fetuses and newborns whose mothers received aspirin before delivery may have plasma concentrations of free salicylate up to four times higher than those of their mothers (Schoenfeld *et al*, 1992). The finding that aspirin exerted chemopreventive efficacy when administered *in utero* and during weaning is consistent with these pharmacokinetic considerations, in that efficacy was probably the consequence of efficacious levels of salicylate in the mother's milk and the embryonic blood and tissues. In contrast, the absorption of curcumin is poor and its systemic availability is extremely low in all species in which it has thus far been tested (Ireson *et al*, 2001). Therefore, when curcumin was administered *in utero* and during weaning in  $Apc^{Min/+}$  mice, levels of drug which reached the maternal blood and milk and the fetal organism were conceivably insufficient to elicit chemopreventive efficacy.

Sequential administration in  $Apc^{Min/+}$  mice of firstly aspirin *in utero* and during weaning and secondly curcumin given postweaning for the remainder of the animals' lifetime decreased mean tumour burden slightly, but not significantly, more than the aspirin-only regimen (Figure 2). The extent of adenoma reduction by the combination was also not superior to intervention with curcumin alone administered postweaning (Figure 2). Analysis of tumour distribution (Figure 3) shows that sequential intervention with aspirin followed by curcumin significantly reduced the number of small adenomas in the proximal and distal regions and of middle-sized adenomas in the middle and distal regions,



**Figure 3** Effect of dietary aspirin (0.05%) administered *in utero* and during weaning (bars 1) or of the combination (bars 2) of aspirin, given as above, with dietary curcumin (0.2%), administered postweaning to the end of the experiment, on multiplicity of small (< 1 mm diameter, open bars) medium size (1–3 mm, hatched bars) or large (> 3 mm, closed bars) adenomas in the proximal (A), middle (B), distal (C) or colonic (D) sections of the intestine of  $Apc^{Min/+}$  mice. Results are expressed as mean number of adenomas over or below mean adenoma numbers in control (untreated)  $Apc^{Min/+}$  mice. Number of mice per group was eight to 10. Asterisk indicates that the number of adenomas in that segment was significantly different from that in the respective segment in control animals ( $P < 0.05$ ). For details of animals and treatments and statistical evaluation see, Materials and Methods.

which is comparable to the efficacy characteristics of curcumin alone (Perkins *et al*, 2002).

Even though aspirin and curcumin are considered to act via similar modes of action by decreasing levels of active COX enzymes, there are clear differences between them as reflected by the age-related discrepancy in susceptibility of Apc<sup>Min/+</sup> mice towards drug activity. On the one hand, aspirin and curcumin seem to exert optimal adenoma-retarding activity at different stages of the lifetime of Apc<sup>Min/+</sup> mice, aspirin early and curcumin late; on the other hand, we failed to observe additivity or synergy when both agents were administered sequentially. Together these findings are consistent with the notion that in this mouse model aspirin and curcumin exert their activities probably on the same cells, but within different 'developmental windows'.

The administration regimens involving aspirin *in utero* and during weaning alone or in combination prior to curcumin had no detrimental effect on propensity towards gastrointestinal bleeding, as reflected by the haematocrit (results not shown), nor did they cause gastric erosion and loss of mucosal integrity, as adjudged by macroscopic inspection. These side effects are often associated with long-term administration of NSAIDs.

## REFERENCES

- Barnes CJ, Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. *Gastroenterology* **114**: 873–877
- Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. *Cancer Res* **56**: 2556–2560
- Chiu CH, McEntee MF, Whelan J (2000) Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. *Prostaglandins Leukot Essent Fatty Acids* **62**: 269–275
- Findlay JW, DeAngelis RL, Kearney MF, Welch RN, Findlay JM (1981) Analgesic drugs in breast milk and plasma. *Clin Pharmacol Ther* **29**: 625–633
- Ireson CR, Orr S, Jones DJL, Verschoyle RD, Lim CK, Williams ML, Howells L, Plummer S, Jukes R, Steward WP, Gescher AJ (2001) Identification of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and rat plasma and evaluation of their ability to interfere with phorbol ester-induced prostaglandin E-2 production. *Cancer Res* **61**: 1058–1064
- Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA (2000a) Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. *Cancer Res* **60**: 1864–1870
- Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000b) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. *Cancer Res* **60**: 5040–5044
- Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. *Cell* **87**: 159–170
- Luongo C, Moser AR, Gledhill S, Dove WF (1994) Loss of Apc+ in intestinal adenomas from Min mice. *Cancer Res* **54**: 5947–5952
- Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM (2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. *Carcinogenesis* **21**: 921–927
- Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. *Surgery* **124**: 225–231
- Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* **247**: 322–324
- Needs CJK, Brooks PM (1985) Clinical pharmacokinetics of the salicylates. *Clin Pharmacokinetics* **10**: 164–177
- Orner G, Dashwood W, Blum C, Diaz G, Li Q, Al-Fageeh M, Tebbutt N, Heath J, Ernst M, Dashwood R (2002) Response of Apc (min) and A33 (deltaNbeta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Mutat Res* **506–507**(C): 121
- Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. *Cancer Epidemiol Biomarkers Prev* **11**: 535–540
- Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. *Oncogene* **18**: 6013–6020
- Reuter BK, Zhang XJ, Miller MJS (2002) Therapeutic utility of aspirin in the Apc<sup>Min/+</sup> murine model of colon carcinogenesis. *BMC Cancer* **2**: 19
- Ritland SR, Gendler SJ (1999) Chemoprevention of intestinal adenomas in the Apc<sup>Min/+</sup> mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. *Carcinogenesis* **20**: 51–58
- Sansom OJ, Stark LA, Dunlop MG, Clarke AR (2001) Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. *Cancer Res* **61**: 7060–7064
- Schoenfeld A, Bar Y, Merlon P, Ovadia Y (1992) NSAIDs: maternal and fetal considerations. *Am J Reprod Immunol* **28**: 141–147
- Shoemaker AR, Moser AR, Dove WF (1995) N-Ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. *Cancer Res* **55**: 4479–4485
- Strumia MM, Sample AB, Hart ED (1954) An improved micro hematocrit method. *Am J Clin Pathol* **24**: 1016–1024
- Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. *Nat Med* **6**: 1024–1028
- Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. *Nat New Biol* **231**: 232–235
- Williamson SL, Kartheuser A, Coaker J, Kooshkghazi MD, Fodde R, Burn J, Mathers JC (1999) Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. *Carcinogenesis* **20**: 805–810